The microbiome space: an emerging research field to be explored

The microbiome is a broad and rich field that influences a multitude of areas, including diagnostics, therapeutics and nutrition.  We are currently witnessing a scientific revolution with regards to microbiome studies. There is a wealth of scientific data to indicate the significance of microbiota in human health and that microbiota composition plays a factor in the onset of numerous conditions including inflammatory diseases, such as Crohn’s disease, infectious diseases, metabolic diseases, such as type 2 diabetes, auto-immune and central nervous system diseases.

Microbiota composition also has an influence on the efficacy of targeted therapies in humans. More specifically, numerous studies suggest that the composition of the microbiome has a genuine influence on the response to immunotherapy drugs for treating cancer or infectious diseases, as well as to antivirals and vaccines.

The microbiome therapeutics space is growing strongly and industrials developing microbiome-based therapies are facing numerous challenges such as identifying and meeting regulatory requirements to gain approval despite the emergence of guidelines.

For instance, Live Biotherapeutics Products (LBPs) require specific considerations for safety and efficacy evaluation due their particular features and mechanisms of action.

Therefore, we anticipate a need for the developers to be supported by non-clinical organizations to demonstrate the value of their therapeutics in terms of quality, safety and efficacy in order to derisk further clinical testing and accelerate time to market.

About us

Based on the preclinical needs of academic research teams and biopharmaceutical companies, Cynbiose launched CYNBIOME, the first excellence network on microbiota which takes full advantage of the synergy between specialized stakeholders by creating a division for the preclinical investigation of the microbiome.

As a first step, CYNBIOME will focus on preclinical research studies on therapeutics targeting infectious diseases but other therapeutic areas will soon be investigated such as oncology and inflammatory disorders.

Cynbiome preclinical network aims to achieve a twofold objective:

  • Offering a unique preclinical range of stand-alone or packaged services in the field of the microbiome and infectious diseases.
    These specialized services will be proposed to the biopharma industry and research teams developing Living Biotherapeutic Products or microbiome-based therapeutics as well as organizations exploring the influence of microbiota on their drug candidates.
    The offer will initially cover preclinical validation of the safety of Living Biotherapeutic Products (LBPs, FMTs), exploratory studies of the mode of action (MOA) as well as the assessment of the microbiome as a biomarker of the efficacy of drug or vaccine candidates, in particular those developed in infectious diseases.
  • Research and Development activities to develop an innovative preclinical model, namely the non-human primate (NHP) model and relevant analytical tools, through collaborative R&D projects.

Cynbiose partners for the Cynbiome network are the companies Active Biomarkers, Biose, Maat Pharma, Biofortis, Hawkcell, Netri, Viroscan3D and the research orgaizations Bioaster, CarMen academic research laboratory, the International Centre for Infectious Disease Research (CIRI) of which the academic research VirPath is a part, the SFR Biosciences et technological research platform VirNext.

This innovative project has procured financing of €1.9 million ($2.1M) under the third phase of the French Program ‘Investment for the Future’ (PiA3). CYNBIOME is financed by the French government and the Auvergne-Rhône-Alpes region and is supported by Bpifrance (The French Public Bank of Investment).